Fragment-Based Screening Identifies Novel Non-Amino Acid Inhibitors of the Sodium-Coupled Neutral Amino Acid Transporter SNAT2.

IF 4.3 3区 医学 Q2 CHEMISTRY, MULTIDISCIPLINARY
Pharmaceutical Research Pub Date : 2025-08-01 Epub Date: 2025-08-08 DOI:10.1007/s11095-025-03902-7
Sebastian Jakobsen, Carsten Uhd Nielsen
{"title":"Fragment-Based Screening Identifies Novel Non-Amino Acid Inhibitors of the Sodium-Coupled Neutral Amino Acid Transporter SNAT2.","authors":"Sebastian Jakobsen, Carsten Uhd Nielsen","doi":"10.1007/s11095-025-03902-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amino acid transporters like the sodium-coupled neutral amino acid transporter 2 (SNAT2, SLC38A2) have gained interest for their roles in, e.g., the central nervous system and in cancer. Efforts in discovering inhibitors against these transporters often result in amino acid-based inhibitors that lack selectivity and are likely to compete with amino acid substrates to bind their targets. To circumvent this, we aimed to discover novel non-amino acid inhibitors of SNAT2 by screening a library of fragment-sized compounds.</p><p><strong>Methods: </strong>320 fragment compounds were screened for their inhibition of <sup>3</sup>H-Gly uptake in hyperosmotically upregulated SNAT2-expressing PC-3 cells. The top five hits were studied further for their inhibitory potency and structure-activity relationship (SAR). Their ability to be translocated by SNAT2 was studied using the FLIPR membrane potential (FMP) assay, as well as their mechanism of inhibition.</p><p><strong>Results: </strong>The screen revealed two similar scaffolds that showed SNAT2 inhibition, namely 1,3-benzothiazole-2-amine and 1,3-benzoxazole-2-amine. The SAR revealed how hydrophobic substituents at specific positions were needed for the structures to show SNAT2 inhibition. The best inhibitors inhibited SNAT2 with IC<sub>50</sub>s in the range of 0.64-1.08 mM. Many of the fragment compounds showed an apparent hyperpolarization in the FMP assay, making it difficult to determine their ability to be translocated by SNAT2. An allosteric mechanism of inhibition was implied for the thiazole and oxazole scaffolds, as these resulted in inhibition patterns that resembled non- or un-competitive inhibitors.</p><p><strong>Conclusion: </strong>In conclusion, we discovered multiple novel non-amino acid compounds that inhibited SNAT2 and can serve as starting points for the further development of SNAT2 inhibitors.</p>","PeriodicalId":20027,"journal":{"name":"Pharmaceutical Research","volume":" ","pages":"1285-1297"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405023/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11095-025-03902-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Amino acid transporters like the sodium-coupled neutral amino acid transporter 2 (SNAT2, SLC38A2) have gained interest for their roles in, e.g., the central nervous system and in cancer. Efforts in discovering inhibitors against these transporters often result in amino acid-based inhibitors that lack selectivity and are likely to compete with amino acid substrates to bind their targets. To circumvent this, we aimed to discover novel non-amino acid inhibitors of SNAT2 by screening a library of fragment-sized compounds.

Methods: 320 fragment compounds were screened for their inhibition of 3H-Gly uptake in hyperosmotically upregulated SNAT2-expressing PC-3 cells. The top five hits were studied further for their inhibitory potency and structure-activity relationship (SAR). Their ability to be translocated by SNAT2 was studied using the FLIPR membrane potential (FMP) assay, as well as their mechanism of inhibition.

Results: The screen revealed two similar scaffolds that showed SNAT2 inhibition, namely 1,3-benzothiazole-2-amine and 1,3-benzoxazole-2-amine. The SAR revealed how hydrophobic substituents at specific positions were needed for the structures to show SNAT2 inhibition. The best inhibitors inhibited SNAT2 with IC50s in the range of 0.64-1.08 mM. Many of the fragment compounds showed an apparent hyperpolarization in the FMP assay, making it difficult to determine their ability to be translocated by SNAT2. An allosteric mechanism of inhibition was implied for the thiazole and oxazole scaffolds, as these resulted in inhibition patterns that resembled non- or un-competitive inhibitors.

Conclusion: In conclusion, we discovered multiple novel non-amino acid compounds that inhibited SNAT2 and can serve as starting points for the further development of SNAT2 inhibitors.

Abstract Image

Abstract Image

Abstract Image

基于片段的筛选鉴定了钠偶联中性氨基酸转运体SNAT2的新型非氨基酸抑制剂。
氨基酸转运体如钠偶联中性氨基酸转运体2 (SNAT2, SLC38A2)因其在中枢神经系统和癌症中的作用而引起了人们的兴趣。发现这些转运蛋白抑制剂的努力往往导致基于氨基酸的抑制剂缺乏选择性,并且可能与氨基酸底物竞争以结合其靶标。为了避免这种情况,我们旨在通过筛选片段大小的化合物文库来发现新的非氨基酸的SNAT2抑制剂。方法:筛选320个片段化合物,以抑制高渗上调的表达snat2的PC-3细胞对3H-Gly的摄取。进一步研究了前5个hit的抑制效能和构效关系(SAR)。利用flir膜电位(FMP)试验研究了它们被SNAT2易位的能力,以及它们的抑制机制。结果:筛选到两个相似的支架,即1,3-苯并噻唑-2-胺和1,3-苯并恶唑-2-胺,显示出对SNAT2的抑制作用。SAR揭示了如何在特定位置需要疏水取代基来显示对SNAT2的抑制。最佳抑制剂的ic50在0.64-1.08 mM范围内抑制了SNAT2。许多片段化合物在FMP实验中表现出明显的超极化,这使得很难确定它们被SNAT2易位的能力。由于噻唑和恶唑支架的抑制模式类似于非竞争性或非竞争性抑制剂,因此暗示了一种变构抑制机制。结论:总之,我们发现了多种抑制SNAT2的新型非氨基酸化合物,可以作为进一步开发SNAT2抑制剂的起点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Research
Pharmaceutical Research 医学-化学综合
CiteScore
6.60
自引率
5.40%
发文量
276
审稿时长
3.4 months
期刊介绍: Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to: -(pre)formulation engineering and processing- computational biopharmaceutics- drug delivery and targeting- molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)- pharmacokinetics, pharmacodynamics and pharmacogenetics. Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信